Investments
NewSpring Capital has taken the lead on financing for Kincellis Advanced Therapies, a newly formed US-based contract development and manufacturing organization (CDMO) focused on cell and advanced-therapy modalities. The company was established through a merger of cell therapy manufacturing operations, bringing together roughly 140,000 square feet of GMP-compliant production space. Kincellis operates across three states: Florida, North Carolina, and Texas. As a CDMO, Kincellis provides development and manufacturing services to biopharmaceutical companies working on cell and advanced therapies. Its GMP facilities are designed to support clinical and commercial production of these complex treatments.
The financing led by NewSpring Capital will support the merged entity’s operations and growth. The deal reflects continued investor interest in the cell therapy sector, where specialized manufacturing capacity remains a critical bottleneck for developers. Kincellis did not disclose the financial terms of the financing.